Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
irinotecan, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving trastuzumab together with irinotecan may kill
more tumor cells.
PURPOSE: This phase II trial is studying how well giving trastuzumab together with irinotecan
works in treating patients with HER2/neu positive metastatic breast cancer.